Flutamide-induced cyanosis refractory to methylene blue therapy. (1996)

Peer-Reviewed Study · Kouides PA, Abboud CN, Fairbanks VF · July 1996

Kouides PA et al., 1996-07: Case report of a man on flutamide for prostate cancer who developed cyanosis and dyspnoea: the CO-oximeter suggested methaemoglobinaemia, methylene blue failed, and the true finding was sulphaemoglobinaemia, which is refractory to methylene blue.

An unsuccessful trial of methylene blue therapy led to the finding of marked sulphaemoglobinaemia. Sulphaemoglobinaemia has not previously been reported with flutamide use. Recognition of this association is important, given the refractoriness of sulphaemoglobinaemia to methylene blue therapy.

Kouides PA et al., 1996-07: Case report of a man on flutamide for prostate cancer who developed cyanosis and dyspnoea: the CO-oximeter suggested methaemoglobinaemia, methylene blue failed, and the true finding was sulphaemoglobinaemia, which is refractory to methylene blue. C8. Study type: case report. N: 1. Country: USA (Mayo Clinic author group). Drug context: flutamide, an anti-androgen used in prostate cancer. Dose/route: methylene blue given therapeutically, dose not stated in the abstract. Funder/conflicts: none declared in the record. Bearing: CONTRADICTS the efficacy reading of C8 (that MB corrects the apparent methaemoglobinaemia) – MB did not work because the pigment was sulphaemoglobin; the row is recorded because C8 asks for documents bearing on measurement interference during prostate-related care. Study type: case report.